NCT00046683View on ClinicalTrials.gov

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

PHASE3CompletedINTERVENTIONAL

Enrollment

284

Participants

Timeline

Start Date

July 31, 2001

Study Completion Date

June 30, 2006

Conditions

B Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

alemtuzumab

Trial Locations (20)

Unknown

Tucson

Little Rock

Fort Myers

Tampa

Hines

Louisville

Paducah

Lafayette

Jackson

Tupelo

Jefferson City

Kansas City

Billings

Omaha

New Hyde Park

Rochester

Durham

Sioux Falls

San Antonio

Norfolk

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00046683 - Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter